Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).


Original post, click here
Experimental: Treatment Arm 1

durvalumab + tremelimumab comination therapy + SoC chemotherapy

Drug: Durvalumab

IV infusions every 3 weeks for 12 weeks (4 cycles) and every 4 weeks thereafter until disease progression or other discontinuation criteria

Drug: Tremelimumab

IV infusions every 3 weeks for 12 weeks (4 cycles). An additional dose of tremelimumab will be administered in the week 16.

Drug: Abraxane + carboplatin

Standard of care chemotherapy (squamous and non-squamous patients)

Drug: Gemcitabine + cisplatin

Standard of care chemotherapy (squamous patients only)

Drug: Gemcitabine + carboplatin

Standard of care chemotherapy (squamous patients only)

Drug: Pemetrexed + carboplatin

Standard of care chemotherapy (non-squamous patients only)

Drug: Pemetrexed + cisplatin

Standard of care chemotherapy (non-squamous patients only)